Analysts who follow Lyell Immunopharma Inc (LYEL) on average expect it to rise 259.55% over the next twelve months. Those same analysts give the stock an average rating of Buy. That average rating earns LYEL an Analyst Ranking of 30, which means it ranks higher than 30 of stocks, based on data compiled by InvestorsObserver.
Wall Street analysts are rating LYEL a Buy today. Find out what this means to you and get the rest of the rankings on LYEL!